|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Genzyme |
| Information provided by: | Genzyme |
| ClinicalTrials.gov Identifier: | NCT00069862 |
Purpose
A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
| Condition | Intervention | Phase |
|
Beta-Thalassemia |
Drug: Deferitrin (GT56-252) Drug: desferoxamine (DFO) |
Phase I Phase II |
| Genetics Home Reference related topics: | beta thalassemia |
| MedlinePlus related topics: | Thalassemia |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study |
| Official Title: | Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | GTC-134-102 |
| First Received: | October 2, 2003 |
| Last Updated: | June 19, 2008 |
| ClinicalTrials.gov Identifier: | NCT00069862 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|